{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=REGN3767", "query": { "intervention": "REGN3767" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=REGN3767&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T02:00:41.424Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06571708", "title": "Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Muscle-Invasive Bladder Carcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2025-08-14", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06571708" }, { "nct_id": "NCT03916627", "title": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Hepatocellular Carcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "cemiplimab", "type": "DRUG" }, { "name": "Platinum Doublet", "type": "DRUG" }, { "name": "fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2019-07-23", "completion_date": "2030-05-14", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03916627" }, { "nct_id": "NCT05137054", "title": "A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Nirogacestat", "type": "DRUG" }, { "name": "Cevostamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2022-08-17", "completion_date": "2032-03-24", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 13, "location_summary": "La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05137054" }, { "nct_id": "NCT05785767", "title": "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "fianlimab", "type": "DRUG" }, { "name": "cemiplimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2023-06-30", "completion_date": "2027-09-28", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 23, "location_summary": "Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Redlands", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Clermont", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785767" }, { "nct_id": "NCT06205836", "title": "Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2024-06-13", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06205836" }, { "nct_id": "NCT05929664", "title": "Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Basal Cell Carcinoma", "Basal Cell Carcinoma" ], "interventions": [ { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Fianlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-07-05", "completion_date": "2031-07-05", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 3, "location_summary": "Miami, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05929664" }, { "nct_id": "NCT06848088", "title": "A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Fianlimab+cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2025-04-14", "completion_date": "2029-10-10", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06848088" }, { "nct_id": "NCT04566978", "title": "89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Large B-cell Lymphoma", "DLBCL" ], "interventions": [ { "name": "89Zr-DFO-REGN3767", "type": "DRUG" }, { "name": "PET/CT", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-09-11", "completion_date": "2025-03-21", "has_results": false, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566978" }, { "nct_id": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Breast Tumors", "Angiosarcoma", "TNBC - Triple-Negative Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Tumor", "Hormone Receptor Negative Tumor", "Early-stage Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "Standard Therapy", "type": "DRUG" }, { "name": "AMG 386 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 479 (Ganitumab) plus Metformin", "type": "DRUG" }, { "name": "MK-2206 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 386 and Trastuzumab", "type": "DRUG" }, { "name": "T-DM1 and Pertuzumab", "type": "DRUG" }, { "name": "Pertuzumab and Trastuzumab", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" }, { "name": "ABT-888", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab - 4 cycle", "type": "DRUG" }, { "name": "Talazoparib plus Irinotecan", "type": "DRUG" }, { "name": "Patritumab and Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab - 8 cycle", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Durvalumab plus Olaparib", "type": "DRUG" }, { "name": "SD-101 + Pembrolizumab", "type": "DRUG" }, { "name": "Tucatinib plus trastuzumab and pertuzumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab plus REGN3767", "type": "DRUG" }, { "name": "Trilaciclib with or without trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "SYD985 ([vic-]trastuzumab duocarmazine)", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab", "type": "DRUG" }, { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Amcenestrant + Abemaciclib", "type": "DRUG" }, { "name": "Amcenestrant + Letrozole", "type": "DRUG" }, { "name": "ARX788", "type": "DRUG" }, { "name": "ARX788 + Cemiplimab", "type": "DRUG" }, { "name": "VV1 + Cemiplimab", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan + Durvalumab", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Lasofoxifene", "type": "DRUG" }, { "name": "Z-endoxifen", "type": "DRUG" }, { "name": "ARV-471", "type": "DRUG" }, { "name": "ARV-471 + Letrozole", "type": "DRUG" }, { "name": "ARV-471 + Abemaciclib", "type": "DRUG" }, { "name": "Endoxifen + Abemaciclib", "type": "DRUG" }, { "name": "Rilvegostomig + TDXd", "type": "DRUG" }, { "name": "Dan222 + Niraparib", "type": "DRUG" }, { "name": "Sarilumab + Cemiplimab + Paclitaxel", "type": "DRUG" }, { "name": "GSK 5733584", "type": "DRUG" }, { "name": "GSK 5733584 + Dostarlimab", "type": "DRUG" }, { "name": "Ivonescimab (20mg/kg Q3W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2010-03-01", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042379" }, { "nct_id": "NCT06769698", "title": "A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)" ], "interventions": [ { "name": "FDC fianlimab+cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-04-14", "completion_date": "2030-12-28", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-16T02:00:41.424Z", "location_count": 18, "location_summary": "Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06769698" } ] }